Synthetic Biologics

 
Stock Quotes for Synthetic Biologics top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Slow Growth
Sign-up for syn investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
  • Stock Type: Slow Growth
Sign-up for syn investment picks

 
News Articles for Synthetic Biologics top ^
2014/8/14
-- Expanded Data from Phase II MS Trial to be Released Next Month; Plans on Course to Advance C.
Sign-up for Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights investment picks
2014/6/25
-- Company's License Covers C-IBS, Type 2 Diabetes and Obesity --
Sign-up for Synthetic Biologics Reports that Licensor Cedars-Sinai Finds Eradication of Gut Methane Improves Insulin Sensitivity and Lipid Profiles in Study of Pre-Diabetic, Obese Patients investment picks
2014/7/21
Company's License from The University of Texas at Austin Covers Development of SYN-005 in Collaboration with Intrexon Corporation ROCKVILLE, Md.
Sign-up for Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference investment picks
2014/8/28
-- Fujifilm's pAVEway™ Platform Demonstrated >25-fold Improvement in SYN-004 Expression Titers --
Sign-up for Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile investment picks
-- Two of Company's Anti-Infective Programs to be Presented at Highly Regarded Scientific Conference: Pertussis and C.
Sign-up for Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC investment picks
-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board --
Sign-up for Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day investment picks
-- SYN-005 Program Targeting Pertussis Toxin to be Highlighted in Oral Presentation --
Sign-up for Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC investment picks
-- Keynote Speaker: Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center; Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board --
Sign-up for Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day investment picks
2014/8/5
-- Executed Agreement with Evonik for Formulation Development, Analytical Services andClinical Drug Manufacturing -- --
Sign-up for Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile investment picks
-- SYN-005 Neutralizing Antibody Combination Protects Against Pertussis in Murine and Non-Human Primate Models --
Sign-up for Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program investment picks
-- Company Completes Final Preclinical Toxicology Study and Prepares to File Investigational New Drug (IND) in 2H 2014 --
Sign-up for Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections investment picks
-- Company Expects to Initiate C.
Sign-up for Synthetic Biologics Forms Clinical Advisory Board to Support Novel C. difficile Preventative Program investment picks
2014/7/31
-- Oral Presentation to Include Greater Detail on Clinical Outcomes, Including Significant and Unique Improvements in Cognition --
Sign-up for Expanded Data on Disability and Cognitive Improvements in Phase II Study of Synthetic Biologics' Trimesta™ in Multiple Sclerosis to be Presented at 2014 Joint ACTRIMS-ECTRIMS Meeting investment picks
-- Company Expects to File IND to Support Clinical Trials in Mid-2015 --
Sign-up for Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis) investment picks
2014/7/29
ROCKVILLE, Md.
Sign-up for Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Synthetic Biologics
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Synthesis Energy Systems  |  Next: Synthetic Fibers